Tab Levoflox

# Tab levoflox ## Overview - **Classification**: Fluoroquinolone antibiotic - **Mechanism**: Inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, repair, and recombination. ## Primary Indications 1. **Community-Acquired Pneumonia (CAP)** - Caused by susceptible organisms 2. **Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB)** - When other agents are not suitable 3. **Complicated Urinary Tract Infections (cUTI) & Pyelonephritis** - Caused by susceptible organisms 4. **Acute Bacterial Sinusitis (ABS)** - When other agents are not suitable 5. **Skin and Skin Structure Infections (SSSI)** - Uncomplicated and complicated ## Adult Dosing ### Standard Dosing **Community-Acquired Pneumonia (CAP), Complicated UTI, Pyelonephritis, Acute Bacterial Sinusitis** - **Dose**: **750 mg** - **Frequency**: Once daily - **Route**: Oral - **Duration**: CAP (5 days), cUTI (5 days), Pyelonephritis (5 days), ABS (5 days) **Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB), Uncomplicated Skin and Skin Structure Infections** - **Dose**: **500 mg** - **Frequency**: Once daily - **Route**: Oral - **Duration**: ABECB (7 days), SSSI (7-14 days) **Complicated Skin and Skin Structure Infections (cSSSI)** - **Dose**: **750 mg** - **Frequency**: Once daily - **Route**: Oral - **Duration**: 7-14 days ### Dose Adjustments - **Renal Impairment**: - **CrCl 20-49 mL/min**: Initial **750 mg**, then **250 mg** q24h for most indications. For **500 mg** initial dose, reduce to **250 mg** q24h. - **CrCl 10-19 mL/min**: Initial **750 mg**, then **250 mg** q48h. For **500 mg** initial dose, reduce to **250 mg** q48h. - **Hemodialysis/CAPD**: Initial **750 mg**, then **250 mg** q48h. Administer after dialysis. - **Hepatic Impairment**: No dosage adjustment required. - **Elderly Patients**: Adjust dose based on renal function; no specific age-related adjustment otherwise. ## Pediatric Dosing **Note**: Use in pediatric patients is generally reserved for specific indications (e.g., anthrax, plague, MDR-TB, complicated UTI where alternatives are not feasible) due to risks of musculoskeletal adverse effects (arthropathy, tendon rupture). ### Neonates (0-28 days) - **Use**: Not generally recommended due to safety concerns and lack of data. - **Special Notes**: Consider only in life-threatening situations with no suitable alternatives, under expert guidance. ### Infants (1-12 months) - **Use**: Not generally recommended due to safety concerns. - **Special Notes**: Use only for specific, severe infections (e.g., anthrax, plague) where benefit outweighs risk and alternatives are unavailable. ### Children (6 months to 12 years) **Complicated Urinary Tract Infection (cUTI) / Pyelonephritis (when alternatives not suitable)** - **Dose**: **10 mg/kg/dose** - **Frequency**: Every 12 hours - **Maximum**: **250 mg/dose** for 6 months to <5 years; **500 mg/dose** for 5 to 12 years. Maximum daily **750 mg**. - **Duration**: 10-14 days **Anthrax (post-exposure), Plague** - **Dose**: **8 mg/kg/dose** (for 6 months to <5 years) or **10 mg/kg/dose** (for 5-12 years) - **Frequency**: Every 12 hours - **Maximum**: **250 mg/dose** (6 months to <5 years); **500 mg/dose** (5-12 years). Max daily **1000 mg**. - **Duration**: Anthrax (60 days), Plague (10-14 days) ### Adolescents (13-18 years) - **Dose**: Generally follow adult dosing recommendations for the specific indication. - **Maximum**: Adult maximum daily dose **750 mg** (or **1000 mg** for specific indications like anthrax). - **Special Notes**: Continue to monitor for musculoskeletal adverse effects. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to levofloxacin or other fluoroquinolones. - **Absolute**: History of tendinitis or tendon rupture associated with fluoroquinolone use. - **Absolute**: Myasthenia Gravis (may exacerbate muscle weakness). - **Relative**: Children <18 years, except for specific indications where benefit outweighs risk. ### Common Adverse Effects - **Common (1-10%)**: Nausea, diarrhea, headache, insomnia, constipation, dizziness. - **Serious but Rare**: Tendinitis and tendon rupture (Boxed Warning), Peripheral neuropathy (Boxed Warning), CNS effects (seizures, psychosis, suicidal thoughts - Boxed Warning), QT prolongation, Torsades de Pointes, Hypo/hyperglycemia, *Clostridioides difficile*-associated diarrhea (CDAD), Aortic aneurysm rupture/dissection (especially elderly, HTN, existing aneurysm). ### Key Drug Interactions - **Corticosteroids**: Increased risk of tendon rupture. Avoid concomitant use if possible. - **Antacids (Mg/Al), Sucralfate, Iron, Zinc, Calcium-containing products**: Decrease levofloxacin absorption. Administer levofloxacin at least 2 hours before or 2 hours after these agents. - **Warfarin**: Enhanced anticoagulant effect, monitor INR closely. - **QT-prolonging drugs (e.g., Class IA/III antiarrhythmics, tricyclic antidepressants)**: Increased risk of QT prolongation. Avoid co-administration if possible. - **NSAIDs**: May increase risk of CNS stimulation and seizures. ## Monitoring & Follow-up - **Before Treatment**: Obtain baseline renal function (CrCl). If risk factors for QT prolongation exist, consider baseline ECG. - **During Treatment**: Monitor renal function in patients with impairment. Monitor blood glucose in diabetic patients. - **Clinical Signs**: Educate patients to report tendon pain/swelling, muscle weakness, numbness/tingling, severe diarrhea, or signs of allergic reaction immediately. ## Clinical Pearls - 💡 **Administration**: Can be taken with or without food. Ensure adequate hydration. - 💡 **Timing**: Avoid taking with dairy products, antacids, or mineral supplements due to reduced absorption. Separate by at least 2 hours. - 💡 **Adherence**: Complete the full course of therapy, even if symptoms improve, to prevent resistance. - 💡 **Sun Sensitivity**: Advise patients on sun protection (sunscreen, protective clothing) due to photosensitivity risk. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.